Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Breast Cancer: Evidence from a General Female Population and a Mammographic Screening Cohort in Sweden.
aspirin
breast cancer
mammographic density
nonsteroidal anti-inflammatory drug
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
11
01
2023
revised:
14
01
2023
accepted:
16
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
A link has been proposed between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of breast cancer. There is, however, insufficient data regarding the subtype and stage of breast cancer, and few studies have assessed the interaction between the use of NSAIDs and breast density or previous breast disorders. There is also a lack of data from population-based studies. We first conducted a nested case-control study within the general female population of Sweden, including 56,480 women with newly diagnosed breast cancer during 2006-2015 and five breast cancer-free women per case as controls, to assess the association of NSAID use with the risk of incident breast cancer, focusing on subtype and stage of breast cancer as well as the interaction between NSAID use and previous breast disorders. We then used the Karolinska Mammography Project for Risk Prediction of Breast Cancer (Karma) cohort to assess the interaction between NSAID use and breast density in relation to the risk of breast cancer. Conditional logistic regression was used to estimate the hazard ratio (HR) and a 95% confidence interval (CI) was used for breast cancer in relation to the use of aspirin and non-aspirin NSAIDs. In the nested case-control study of the general population, exclusive use of aspirin was not associated with the risk of breast cancer, whereas exclusive use of non-aspirin NSAIDs was associated with a modestly higher risk of stage 0-2 breast cancer (HR: 1.05; 95% CI: 1.02-1.08) but a lower risk of stage 3-4 breast cancer (HR 0.80; 95% CI: 0.73-0.88). There was also a statistically significant interaction between the exclusive use of NSAIDs and previous breast disorders (
Identifiants
pubmed: 36765650
pii: cancers15030692
doi: 10.3390/cancers15030692
pmc: PMC9913077
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : China Scholarship Council
ID : 201806240005
Organisme : Swedish Cancer Society
ID : 20 0846 PjF
Références
Nat Commun. 2016 Mar 01;7:10634
pubmed: 26925549
Int J Cancer. 2018 Oct 1;143(7):1688-1695
pubmed: 29707771
Int J Cancer. 2019 Jul 1;145(1):267-273
pubmed: 30575949
Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):223-227
pubmed: 27889931
Breast Cancer Res. 2020 Oct 31;22(1):118
pubmed: 33129324
Breast Cancer Res. 2020 Sep 4;22(1):96
pubmed: 32887656
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Int J Epidemiol. 2017 Dec 1;46(6):1740-1741g
pubmed: 28180256
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1645-55
pubmed: 26315555
Cancer Causes Control. 2020 Sep;31(9):827-837
pubmed: 32476101
Am J Epidemiol. 1989 Jan;129(1):212-9
pubmed: 2910063
Ann Intern Med. 2013 Jul 16;159(2):77-85
pubmed: 23856681
BMC Cancer. 2016 Aug 20;16(1):660
pubmed: 27542890
Acta Oncol. 2009;48(1):27-33
pubmed: 18767000
J Clin Oncol. 2019 Mar 10;37(8):624-635
pubmed: 30702971
Cancer. 2006 Apr 1;106(7):1443-52
pubmed: 16502408
Methods Mol Biol. 2011;675:215-20
pubmed: 20949391
Lancet Oncol. 2012 May;13(5):518-27
pubmed: 22440112
J Natl Cancer Inst. 2005 Jun 1;97(11):805-12
pubmed: 15928301
Breast Cancer Res Treat. 2012 Jan;131(2):581-7
pubmed: 21898115
Geburtshilfe Frauenheilkd. 2012 Aug;72(8):727-733
pubmed: 25258465
Breast Cancer Res Treat. 2018 Jun;169(2):371-379
pubmed: 29392583
Int J Epidemiol. 2012 Oct;41(5):1480-9
pubmed: 23045208
Breast Cancer Res Treat. 2014 Jul;146(2):439-46
pubmed: 24986698
World J Clin Oncol. 2014 Oct 10;5(4):677-92
pubmed: 25302170
Health Policy. 2016 Mar;120(3):327-33
pubmed: 26861972
JAMA. 2005 Jul 6;294(1):47-55
pubmed: 15998890
Breast Cancer Res Treat. 2015 Jan;149(2):525-36
pubmed: 25589172
N Engl J Med. 2020 Mar 12;382(11):1018-1028
pubmed: 32160663
N Engl J Med. 2005 Jul 21;353(3):229-37
pubmed: 16034008
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Cancer Prev Res (Phila). 2020 Nov;13(11):967-976
pubmed: 32718942
Am J Epidemiol. 2003 Nov 1;158(9):915-20
pubmed: 14585769
Breast Cancer Res. 2017 May 1;19(1):52
pubmed: 28460643
J Clin Oncol. 2012 Oct 1;30(28):3468-77
pubmed: 22927520
J Natl Cancer Inst. 2020 Apr 1;112(4):391-399
pubmed: 31298705
Clin Cancer Res. 2014 Mar 1;20(5):1104-13
pubmed: 24311630
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Br J Cancer. 2013 Oct 1;109(7):1921-5
pubmed: 23887604
Eur J Epidemiol. 2016 Feb;31(2):125-36
pubmed: 26769609
Breast Cancer Res Treat. 2017 Apr;162(3):419-425
pubmed: 28160159
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Nat Rev Cancer. 2018 Aug;18(8):485-499
pubmed: 29703913
Medicine (Baltimore). 2020 Sep 18;99(38):e21917
pubmed: 32957311
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
Clin Breast Cancer. 2021 Dec;21(6):552-565
pubmed: 33741292
BMC Public Health. 2019 May 2;19(1):495
pubmed: 31046737
Breast Cancer Res Treat. 2015 Aug;153(1):89-99
pubmed: 26227474